A workshop at the National Cancer Institute May 2, 2016 considered the current state of imaging in assessment of immunotherapy. Immunotherapy has shown some remarkable and prolonged responses in the treatment of tumors. However, responses are variable and frequently delayed, complicating the evaluation of new immunotherapy agents and customizing treatment for individual patients. Early anatomic imaging may show that a tumor has increased in size, but this could represent pseudoprogression. Based on imaging, clinicians must decide if they should stop, pause, or continue treatment. Other imaging technologies and approaches are being developed to improve the measurement of response in patients receiving immunotherapy. Imaging methods being evaluated include radiomic methods using computed tomography (CT), magnetic resonance imaging (MRI) and (18)F-FDG-PET (fluorodeoxyglucose-positron emission tomography) as well as new radiolabeled small molecules, antibodies, and antibody fragments to image the tumor microenvironment, immune status and changes over the course of therapy. Current studies of immunotherapy can take advantage of these available imaging options to explore and validate their use. Collection of CT, PET, and MR images along with outcomes from trials are critical to develop improved methods of assessment.